Resource utilization and treatment costs of patients with severe hemophilia A: Real‐world data from the ATHNdataset-Reference-Cited by-同舟云学术

Resource utilization and treatment costs of patients with severe hemophilia A: Real‐world data from the ATHNdataset

Published:2022-03-27 Issue:2 Volume:3 Page:341-352
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Recht Michael¹,He Chunla¹,Chen Er.²,Cheng Dunlei¹,Solari Paul²,Hinds David²^ORCID

Affiliation:

1. American Thrombosis and Hemostasis Network (ATHN) Rochester New York USA

2. BioMarin Pharmaceutical, Inc. (BioMarin) Novato CA USA

Publisher

Wiley

Subject

General Earth and Planetary Sciences

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.412

Reference45 articles.

1. National Hemophilia Association.Hemophilia A.2020[cited 2021 Jan 7]. Available from:https://www.hemophilia.org/bleeding‐disorders‐a‐z/types/hemophilia‐a

2. Textbook of Hemophilia

3. Occurrence of hemophilia in the United States

4. Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres

5. Centers for Disease Control and Prevention.Data and statistics on hemophilia.2020[cited 2021 Jan 7]. Available from:https://www.cdc.gov/ncbddd/hemophilia/data.html

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging approaches to induce immune tolerance to therapeutic proteins;Trends in Pharmacological Sciences;2023-12

2. Healthcare costs among hemophilia A patients in the United States treated with rurioctocog alfa pegol (FVIII-PEG) or antihemophilic factor (recombinant), FC fusion protein (rFVIIIFc) using real-world data;Journal of Medical Economics;2023-10-25

3. Psychometrics and applications of a novel self‐report measure of emicizumab adherence: VERITASNexGen;Haemophilia;2023-08-30

4. Health care costs and resource use of managing hemophilia A: A targeted literature review;Journal of Managed Care & Specialty Pharmacy;2023-06